BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19620494)

  • 1. Generation of a concise gene panel for outcome prediction in urinary bladder cancer.
    Mitra AP; Pagliarulo V; Yang D; Waldman FM; Datar RH; Skinner DG; Groshen S; Cote RJ
    J Clin Oncol; 2009 Aug; 27(24):3929-37. PubMed ID: 19620494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles.
    Birkhahn M; Mitra AP; Williams AJ; Lam G; Ye W; Datar RH; Balic M; Groshen S; Steven KE; Cote RJ
    Eur Urol; 2010 Jan; 57(1):12-20. PubMed ID: 19762144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfatase-1 overexpression indicates poor prognosis in urothelial carcinoma of the urinary bladder and upper tract.
    Lee HY; Yeh BW; Chan TC; Yang KF; Li WM; Huang CN; Ke HL; Li CC; Yeh HC; Liang PI; Shiue YL; Wu WJ; Li CF
    Oncotarget; 2017 Jul; 8(29):47216-47229. PubMed ID: 28525382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer.
    Mitra AP; Almal AA; George B; Fry DW; Lenehan PF; Pagliarulo V; Cote RJ; Datar RH; Worzel WP
    BMC Cancer; 2006 Jun; 6():159. PubMed ID: 16780590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.
    McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO
    Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
    Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
    Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA.
    Morera DS; Hasanali SL; Belew D; Ghosh S; Klaassen Z; Jordan AR; Wang J; Terris MK; Bollag RJ; Merseburger AS; Stenzl A; Soloway MS; Lokeshwar VB
    J Urol; 2020 Jan; 203(1):62-72. PubMed ID: 31112107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.
    Liang PI; Wang YH; Wu TF; Wu WR; Liao AC; Shen KH; Hsing CH; Shiue YL; Huang HY; Hsu HP; Chen LT; Lin CY; Tai C; Wu JY; Li CF
    J Clin Pathol; 2013 Jul; 66(7):573-82. PubMed ID: 23539739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1.
    Rausch S; Hennenlotter J; Teepe K; Kuehs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
    Urol Oncol; 2015 Oct; 33(10):426.e21-9. PubMed ID: 26231311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPX2 underexpression indicates poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder.
    Chang IW; Lin VC; Hung CH; Wang HP; Lin YY; Wu WJ; Huang CN; Li CC; Li WM; Wu JY; Li CF
    World J Urol; 2015 Nov; 33(11):1777-89. PubMed ID: 25813210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma.
    Bao Z; Zhang W; Dong D
    Oncotarget; 2017 Feb; 8(6):10485-10497. PubMed ID: 28060759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer.
    Duan W; Du L; Jiang X; Wang R; Yan S; Xie Y; Yan K; Wang Q; Wang L; Zhang X; Pan H; Yang Y; Wang C
    Oncotarget; 2016 Nov; 7(48):78850-78858. PubMed ID: 27793008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serine threonine kinase 15 amplification in normal urothelium of cystectomy specimens is no prognostic factor in urothelial carcinoma of the bladder.
    Otto W; Fritsche HM; Wild PJ; Wieland WF; Hartmann A; Burger M; Hofstädter F; Denzinger S
    Pathol Res Pract; 2011 Mar; 207(3):161-3. PubMed ID: 21247708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
    Klatte T; Seligson DB; Rao JY; Yu H; de Martino M; Kawaoka K; Wong SG; Belldegrun AS; Pantuck AJ
    Cancer; 2009 Apr; 115(7):1448-58. PubMed ID: 19195047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder.
    Bartsch G; Mitra AP; Mitra SA; Almal AA; Steven KE; Skinner DG; Fry DW; Lenehan PF; Worzel WP; Cote RJ
    J Urol; 2016 Feb; 195(2):493-8. PubMed ID: 26459038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.
    Le Goux C; Vacher S; Schnitzler A; Barry Delongchamps N; Zerbib M; Peyromaure M; Sibony M; Allory Y; Bieche I; Damotte D; Pignot G
    Sci Rep; 2020 Oct; 10(1):16641. PubMed ID: 33024200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival.
    Luo JH; Xie D; Liu MZ; Chen W; Liu YD; Wu GQ; Kung HF; Zeng YX; Guan XY
    Int J Cancer; 2008 Jun; 122(11):2554-61. PubMed ID: 18246597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGF7 Over Expression is an Independent Prognosticator in Patients with Urothelial Carcinoma of the Upper Urinary Tract and Bladder.
    Fan EW; Li CC; Wu WJ; Huang CN; Li WM; Ke HL; Yeh HC; Wu TF; Liang PI; Ma LJ; Li CF
    J Urol; 2015 Jul; 194(1):223-9. PubMed ID: 25623741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An autophagy-related long non-coding RNA prognostic signature accurately predicts survival outcomes in bladder urothelial carcinoma patients.
    Sun Z; Jing C; Xiao C; Li T
    Aging (Albany NY); 2020 Aug; 12(15):15624-15637. PubMed ID: 32805727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.